Targeted bacteriophage technology...

safeguarding human and animal health...

by harnessing sustainable, natural,
antibacterial technology.


The technologies developed by Fixed Phage are platform technologies and have the ability to address a wide range of applications in society.

This flexibility derives from the underpinning immobilisation technology, which can coat a diverse range of substrates with phages, thereby giving the base substrate inherent anti-microbial properties.

The patented immobilisation technology can allow us to fix phages onto substrates as diverse as plastic sheets and powders.


We work with both leading commercial partners as well as academia to deliver products that target specific bacterial issues within our core areas of industry.

Each of our partners has different capabilities that complement our own and together we design projects that have defined outcomes, whether that is creation of a new product range or pushing forward the boundaries of science.

News & Press

Fixed Phage appoints Chief Commercial Officer to accelerate the commercialisation of its proprietary anti-bacterial platform

Fixed Phage, (the “Company”) the UK biotechnology company developing and commercialising unique, anti-infective technologies based on bacteriophage immobilisation and stabilisation, today announces the appointment of Dr Gordon Jamieson as Chief […]

Read more >
Carus Animal Health and Fixed Phage to collaborate on anti-bacterial solutions to companion animal diseases

Carus Animal Health and British biotechnology company, Fixed Phage, have agreed a strategic collaboration in the companion animal field to identify, develop and commercialise stable and specific bacteriophages and their application […]

Read more >
Innovation Award for fighting bacteria in aquaculture

In competition with 18 companies at Seafood Innovation Day NASF 2018, the seafood industry’s own innovation award went to Scottish Innovation Company Fixed Phage, which develops products that can fight […]

Read more >